BioNTech (BNTX) stock is down nearly 20% at the time of writing after the German company posted a Q4 loss, issued muted guidance, and said its cofounders will depart by the end of this year

CEO Uğur Şahin and Chief Medical Officer Özlem Türeci, who founded BNTX during the financial crisis in 2008, will leave and launch a new biotech startup in late 2026, the press release confirmed.

Stock Index Futures Turn Lower as Bond Yields Climb

2 Ways to Profit from a Fading Tesla Stock Price

Cathie Wood Bets $19 Million on 5 Beaten-Down Stocks

Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else.

Versus its year-to-date high, BioNTech stock is now down roughly 30%.

BNTX stock is worth buying on the dip today as the market seems to be misinterpreting the upcoming leadership change.

While investors are reading it as a sign of instability ahead, it could actually prove notably positive for the firm’s long-term health. Why? Because BioNTech SE said it will “contribute related rights and mRNA technologies” to its cofounders’ new startup in exchange for a minority stake and milestone payments.

This means BioNTech is pivoting to a low-risk, high-reward model. Spinning off early-stage R&D to the new company will enable it to lower its overhead costs while retaining call options via sales royalties.

In short, it plans on outsourcing innovation to its cofounders, positioning itself to focus entirely on development to become a multi-product powerhouse by 2030.

Outsourcing costly early-stage R&D will help BNTX reallocate capital to its high-potential assets, including the PD-L1/VEGF for advanced cancers.

Meanwhile, the biotech firm is scheduled for another seven late-stage data readouts this year, which could help unlock significant further upside in its stock price.

Investors should also consider loading up on BioNTech shares because the crash this morning pushed its relative strength index (14-day) into the mid-20s, indicating potential for a near-term rebound.

Plus, the company’s price-to-sales (P/S) multiple now sits at less than 7x, making it inexpensive to own compared to its industry peers in 2026.

Investors could also take heart in the fact that investors haven’t thrown in the towel on BioNTech yet.

The consensus rating on BNTX shares remains at “Strong Buy”, with the mean target of about $142 indicating potential upside of roughly 70% from here.

This article was created with the support of automated content tools from our partners at Sigma.AI. Together, our financial data and AI solutions help us to deliver more informed market headline analysis to readers faster than ever.

On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com